First personalised cancer vaccine cuts risk of disease returning in major trial

• Personalised cancer vaccines have demonstrated efficacy in reducing recurrence risk in clinical trials, representing a significant advance in individualised cancer treatment approaches
• This development marks progress toward routine integration of bespoke immunotherapies into standard cancer care pathways
• Results suggest potential to shift cancer management paradigm from one-size-fits-all treatments toward tailored therapeutic strategies based on individual tumour profiles

The scientists involved say the results could mark a turning point in cancer treatment, bringing personalised medicine a step closer.

ClinicaliQ summarises and contextualises external updates for clinical awareness, then links to the original publisher for the full article and most current context.